AstraZeneca Annual Report and Form 20-F Information 2008

CEO, Delegation of Authority and Senior Executive Team

CHIEF EXECUTIVE OFFICER AND DELEGATION OF AUTHORITY

The Chief Executive Officer has been delegated authority from, and is responsible to, the Board of AstraZeneca PLC for directing and promoting the profitable operation and development of the Company, consistent with the primary aim of enhancing long-term shareholder value, in relation to all matters save those which have been specifically reserved for the Board.

The Chief Executive Officer is responsible to the Board for the management and performance of the Company’s business within the framework of Company policies, reserved powers and routine reporting requirements. He is obliged to refer certain major matters (defined in the formal delegation of the Board’s authority) back to the Board. The roles of the Board and the relationship between each of the Board’s committees, the Chairman, the Chief Executive Officer and the Senior Executive Team are documented, as are the Board’s delegated authorities and reserved powers, the means of operation of the business and the roles of corporate functions.

SENIOR EXECUTIVE TEAM (SET)

The Chief Executive Officer has established and chairs the SET (above). Although the Chief Executive Officer retains full responsibility for the authority delegated to him by the Board, the SET is the vehicle through which he has chosen to exercise certain of that authority in respect of the Group’s business. The SET normally meets once a month to consider and decide major business issues. Typically, it also reviews those matters that are of a size or importance to require the attention of, or that are reserved to, the Board before such matters are submitted to the Board for review and decision.

John Patterson, Executive Director, Development stepped down from his operational position at the end of January 2009 and will retire from the Board on 31 March 2009.

Anders Ekblom was appointed Executive Vice-President, Development and Jeffrey Pott was appointed General Counsel, both with effect from 1 January 2009 when they both became members of the SET.

In July 2008, David Mott resigned from his position as President and Chief Executive Officer of MedImmune to pursue his career outside AstraZeneca. Tony Zook was appointed President of MedImmune with effect from 13 November 2008, having held the position of interim head of MedImmune since David Mott’s resignation. Tony Zook retains his other responsibilities as Chief Executive Officer, North America and Executive Vice-President, Global Marketing.

Back to the top